Healthcare systems are struggling with balancing uncertainty and providing access to innovative health technologies.
A comprehensive literature review of the trends, challenges, and opportunities in key international markets was conducted by the authors to provide clarity on the feasibility of negotiating outcomes-based agreements.
Although payers’ and manufacturers’ objectives will never align completely, both parties ultimately have a common interest: to ensure that patients have timely and affordable access to innovative medicines. Managed entry agreements can play a crucial role in achieving that goal.
